Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial.
Saved in:
| Title: | Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial. |
|---|---|
| Authors: | Loges S; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany. s.loges@dkfz-heidelberg.de.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany. s.loges@dkfz-heidelberg.de.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. s.loges@dkfz-heidelberg.de., Heuser M; Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.; Comprehensive Cancer Center Niedersachsen, Hannover Medical School, Hannover, Germany., Chromik J; University Hospital Frankfurt, Frankfurt, Germany., Sutamtewagul G; University of Iowa Hospitals and Clinics, Iowa City, IA, US., Kapp-Schwoerer S; University Hospital of Ulm, Ulm, Germany., Crugnola M; University of Parma, Parma, Italy., Di Renzo N; Haematology and Stem Cell Transplantation Unit, Vito Fazzi Hospital, Lecce, Italy., Lemoli R; Department of Internal medicine (DIMI), University of Genoa, Genoa, Italy.; IRCCS-San Martino Hospital, Genoa, Italy., Mattei D; Azienda Sanitaria Ospedaliera (ASO) Santa Croce e Carle, Cuneo, Italy., Fiedler W; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Alvarado-Valero Y; The University of Texas M.D. Anderson Cancer Center, Houston, TX, US., Ben-Batalla I; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Waizenegger J; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Rieckmann LM; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Janning M; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Collienne M; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Imbusch CD; Division of Applied Bioinformatics (B330), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Immunology, University Medical Center Mainz, Mainz, Germany and Research Center for Immunotherapy (FZI), Mainz, Germany., Beumer N; German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; Division of Applied Bioinformatics (B330), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Institute of Immunology, University Medical Center Mainz, Mainz, Germany and Research Center for Immunotherapy (FZI), Mainz, Germany., Micklem D; BerGenBio ASA, Bergen, Norway., H Nilsson L; BerGenBio ASA, Bergen, Norway., Madeleine N; BerGenBio ASA, Bergen, Norway., McCracken N; BerGenBio Ltd, Oxford, UK., Oliva C; BerGenBio Ltd, Oxford, UK., Gorcea-Carson C; BerGenBio Ltd, Oxford, UK., Gjertsen BT; Haukeland University Hospital, Bergen, Norway, & Centre for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway. |
| Source: | Nature communications [Nat Commun] 2025 Mar 23; Vol. 16 (1), pp. 2846. Date of Electronic Publication: 2025 Mar 23. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-58179-6 |
